SYDNEY, July 10, 2023 /PRNewswire/ — Race Oncology Limited (“Race”) is pleased to announce execution of an exclusive licence agreement (“Agreement”) to access U.S. cancer research and treatment organisation City of Hope’s intellectual property (“IP) which highlights bisantrene as a…